Ancora Advisors’s Gyre Therapeutics GYRE Stock Holding History

Ancora Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-63	Closed	-$139K	–	506
2015 Q2	$139K	Buy	+63	New	+$126K	0.02%	479
2015 Q1	–	Hold	0	–	–	–	471
2014 Q4	–	Sell	-96	Closed	-$191K	–	502
2014 Q3	$191K	Buy	96 +76	+380%	+$188K	0.02%	429
2014 Q2	$70K	Buy	+20	New	+$65.3K	0.01%	465
2013 Q4	–	Sell	-63	Closed	-$266K	–	426
2013 Q3	$266K	Sell	63 -11	-15%	-$44.3K	0.05%	326
2013 Q2	$249K	Buy	+74	New	+$282K	0.04%	349

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Ancora Advisors's GYRE Position: Q3 2015 in Review

Ancora Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2015, closing a stake of 63 shares — an estimated $139K sold.

Ancora Advisors first reported a position in GYRE in Q2 2013 and held it in 5 quarters. The position peaked at $266K in Q3 2013. 39 funds tracked by Wall St. Rank hold GYRE as of Q3 2015.

Ancora Advisors reported no remaining Gyre Therapeutics position as of Q3 2015 after selling out during the quarter.
Ancora Advisors sold 63 Gyre Therapeutics shares in Q3 2015, an estimated $139K.
Ancora Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 5 quarters.
Ancora Advisors's Gyre Therapeutics position peaked at $266K in Q3 2013.
39 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2015.

Based on Ancora Advisors's 13F filing for Q3 2015, filed 30 Oct 2015.